T-Cell Subsets Predict Mortality in Malnourished Zambian Adults Initiating Antiretroviral Therapy by Chisenga, CC et al.
T-Cell Subsets Predict Mortality in Malnourished Zambian Adults Initiating
Antiretroviral Therapy.
Chisenga, CC; Filteau, S; Siame, J; Chisenga, M; Prendergast, AJ; Kelly, P
 
 
 
 
 
© 2015 Chisenga et al.
CC-BY
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/8205
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
RESEARCH ARTICLE
T-Cell Subsets Predict Mortality in
Malnourished Zambian Adults Initiating
Antiretroviral Therapy
Caroline C. Chisenga1,2*, Suzanne Filteau2,3, Joshua Siame2, Molly Chisenga2, Andrew
J. Prendergast4, Paul Kelly1,2,3,4
1 Tropical Gastroenterology and Nutrition group, University of Zambia School of Medicine, Lusaka, Zambia,
2 NUSTART project, University Teaching Hospital, Lusaka, Zambia, 3 London School of Hygiene & Tropical
Medicine, London, United Kingdom, 4 Barts & The London School of Medicine, Queen Mary University of
London, London, United Kingdom
* carolle52000@yahoo.co.uk
Abstract
Objective
To estimate the prognostic value of T-cell subsets in Zambian patients initiating antiretrovi-
ral therapy (ART), and to assess the impact of a nutritional intervention on T-cell subsets.
Methods
This was a sub-study of a randomised clinical trial of a nutritional intervention for malnour-
ished adults initiating ART. Participants in a randomised controlled trial (NUSTART trial)
were enrolled between April and December 2012. Participants received lipid-based nutri-
tional supplement either with or without additional vitamins and minerals. Immunophenotyp-
ing was undertaken at baseline and, in survivors, after 12 weeks of ART to characterize T-
cell subsets using the markers CD3, CD4, CD8, CD45RA, CCR7, CD28, CD57, CD31,
α4β7, Ki67, CD25 and HLA-DR. Univariate and multivariate survival analysis was per-
formed, and responses to treatment were analysed using the Wicoxon rank-sum test.
Results
Among 181 adults, 36 (20%) died by 12 weeks after starting ART. In univariate analysis,
patients who died had fewer proliferating, more naïve and fewer gut homing CD4+ T-cells
compared to survivors; and more senescent and fewer proliferating CD8+ T-cells. In a multi-
variate Cox regression model high naïve CD4+, low proliferating CD4+, high senescent
CD8+ and low proliferating CD8+ subsets were independently associated with increased
risk of death. Recent CD4+ thymic emigrants increased less between recruitment and 12
weeks of ART in the intervention group compared to the control group.
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Conclusions
Specific CD4+ T-cell subsets are of considerable prognostic significance for patients initiat-
ing ART in Zambia, but only thymic output responded to this nutritional intervention.
Introduction
Although the annual number of AIDS-related deaths has declined from 2.3 (2.1–2.6) million in
2005, to 1.6 (1.4–1.9) million in 2012 [1] with the expansion of antiretroviral therapy (ART)
provision in sub-Saharan Africa, studies consistently report high mortality during the first 6
months following ART initiation [2,3]. The total CD4+ T-cell count at ART initiation has
important prognostic implications [4,5]. However, there is very little evidence regarding the
prognostic value of specific T-cell subsets on early mortality [6,7].
Studies that have evaluated baseline T-cell subsets have reported that, in HIV-infected
untreated adults, more activated CD8+ T-cells [7], and fewer CD28+ CD4+ T-cells [8] or naïve
CD4+ T-cells independently predicted mortality [9]. In recently HIV-infected and untreated
adults, low proportions of senescent (CD57+) CD4+ T-cells were associated with 5-fold higher
odds of mortality [8]. In Zambian children, more CD8+ effector T-cells with fewer CD4+ cen-
tral memory T-cells was associated with increased risk of mortality [6].
Several studies in Europe and Africa have shown associations between early mortality and
low body mass index and deficiencies in micronutrients at ART initiation [10,11,12,13,14].
However, randomised controlled trials of nutritional supplements, conducted in both children
and adults, have not shown a clear benefit on mortality [15,16,17]. Researchers have also
reported an insignificant increase in CD4+ cell count following macronutrient supplementa-
tion [15]. However, there is emerging evidence that micronutrient supplementation increases
absolute CD4+ cell counts [16,17].
This study was designed to investigate, first, whether specific T-cell subsets predict mortality
in a cohort of HIV-infected Zambian adults initiating ART and, second, whether a nutritional
intervention impacts T-cell subsets in survivors.
Methods
NUSTART Trial Design and Population
We report a sub-study of a randomized controlled trial (Nutritional Support for Africans start-
ing ART, NUSTART) of a vitamin and mineral intervention for HIV-infected adults initiating
ART, full details of which are reported elsewhere [17]. Participants were recruited in Lusaka,
Zambia and Mwanza, Tanzania from August 2011 to December 2013. NUSTART was a phase
III individually randomised controlled trial which compared, in a two-stage protocol, vitamins
and minerals in a lipid-based nutritional supplement (LNS-VM) with unfortified LNS (LNS)
given from recruitment (referral for ART) until 6 weeks after starting ART (S1 Table). In the
first stage, from referral until 2 weeks after ART initiation, the active and control supplements
were given with minimal calories i.e. 30 g/day, 100 kcal/day, only as the lipid-based carrier,
then from 2–6 weeks after ART initiation, patients were given 250 g/day, in two 125 g sachets,
comprising 1360 kcal/day in a calorie-rich supplement. Compliance to ART was high:
95% of patients took at least 95% of medication [17]. The NUSTART trial is registered as
PACTR201106000300631.
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funding. However, beyond taste testing and quality
control (re-testing supplements after periods of
storage in study pharmacies) Nutriset played no role
in analysis, the decision to publish, or the writing of
the manuscript. The contribution of Nutriset does not
alter the authors' adherence to PLOS ONE policies
on sharing data and material.
Sub-study Design and Patient Profile
All adults recruited into the NUSTART trial in Lusaka between April and December 2012 were
eligible for this sub-study. Enrolment occurred at 6 different public clinics during routine assess-
ment for ART eligibility. Following enrolment, a baseline questionnaire was administered and
anthropometric and clinical data collected. All adults eligible for ART (CD4 count<350 cells/μL
and/or WHO stage III or stage IV disease) with body mass index (BMI) of<18.5 kg/m2 were eli-
gible for the NUSTART trial. Over 90% of NUSTART trial patients in Lusaka started a first-line
regimen of tenofovir, emtricitabine and efavirenz, with cotrimoxazole.
Ascertainment of outcome and follow-up
The primary endpoint for the main NUSTART trial was mortality between the time of recruit-
ment (referral for ART) and 12 weeks after starting ART. NUSTART study participants were
followed up weekly before starting ART and at weeks 2, 4, 6, 8 and 12 after ART initiation.
Whether the patient was still alive, and the date of death if not, were ascertained by phone con-
tact or home visit if the patient failed to return to the next scheduled visit. Patients were evalu-
ated at 12 weeks following ART initiation and immunophenotyping was carried out on
baseline and 12 week blood samples.
Grip Strength
The maximum isometric strength of the hand and forearm muscles was measured using a grip
strength dynamometer (Takei, Japan). The handle for the machine was positioned so there was
a 90-degree angle in the second joint of the index finger. The participant then squeezed the
handle as hard as possible once for four times in the following order: right-left-right-left. The
instrument calculated the average of these measurements.
Samples
At recruitment and at week 12 following initiation of ART, 3–5 ml of peripheral blood was col-
lected into an EDTA tube for lymphocyte analysis. Blood samples reached the laboratory
within 1h of collection and were subdivided for haemoglobin and immunophenotyping. Hae-
moglobin was measured on a Sysmex xt 4000i automated haematology analyser (Sysmex Cor-
poration, Kobe, Japan). For immunophenotyping, samples were stained and analysed where
possible within 2 hours by flow cytometry, after being suspended in paraformaldehyde; where
this was not possible, stained samples were suspended in BD CellFix and flow cytometry
undertaken the following day.
Laboratory assays
Immunophenotyping was done using fluorescent-labelled monoclonal antibodies to differenti-
ate T-cell subsets, using CD3 APC-H7 (clone SK7), CD4 FITC (clone RPA-T4) or CD4 PerCP
(clone L200), CD8 FITC (clone 3B5), HLA-DR APC (clone TU36), Ki67 FITC (clone B56),
CCR7 PE (clone 150503), CD25 PE-Cy7 (clone M-A251), Alpha-4 FITC (clone 9F10), Beta-7
APC (clone FIB504), CD57 APC (clone NK-1), CD27 APC or PE-Cy7 (clone M-T271), CD28
FITC or PE (clone CD28.2), CD31 PE (clone WM59), CD45RA PE-Cy7 (clone HI100) and
7-AAD PerCP (all from BD Biosciences, Gauteng, South Africa) in panels, as outlined below.
Data were acquired on a six-colour FACSverse flow cytometer (Becton Dickinson, San Jose, U.
S.A.). 100 μL of whole blood was stained, red cells were lysed, then cells were washed and resus-
pended in 250 μL paraformaldehyde or 10% cell fix before flow cytometric analysis. Intracellu-
lar Ki-67 staining was carried out after resuspension in 1X Perm solution (BD) for nuclear
T Cell Subsets and Mortality
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membrane permeabilisation. Between 50,000–100,000 lymphocyte events were acquired per
tube and fluorescence-minus-one (FMO) controls were used to set all gates. Analysis of mark-
ers was carried out using BD FACSuiteTM software v1.0.2.
CD4+ and CD8+ T-cell Subset Definition
Lymphocytes were gated on CD3+ and CD4+ or CD8+ to identify T-cell populations, and sub-
sets distinguished as follows: naïve (CCR7+CD45RA+), central memory (CCR7+CD45RA-),
effector memory (CCR7-CD45RA-), effector (CD45RA+CCR7-), gut homing (α4+β7+), acti-
vated gut homing (α4+β7+CD25+), recent thymic emigrants (CD45RA+CD31+), activated
(HLA-DR+), proliferating (Ki67+), activated and proliferating (Ki67+ HLA-DR+), or senescent
(CD57+).
Data Analysis
T-cell markers were found to be non-parametrically distributed using the Shapiro-Wilk W’ test
for normality, so results were expressed as medians and interquartile ranges, and variables
compared using the Mann-Whitney U test, or the Wilcoxon rank sum test for paired variables.
P values less than 0.05 were considered statistically significant. For analysis of predictors of
mortality, all cellular subsets plus total CD4+ and CD8+ count, BMI, haemoglobin, sex and grip
strength were included in univariate analysis and p values calculated using Fisher’s exact test
for unpaired variables. In multivariate analysis, all cellular subsets including total CD4+ and
CD8+ count, BMI, haemoglobin, sex and grip strength were included and hazard ratios and p
values determined using the Cox regression model. For both univariate and multivariate analy-
sis, T-cell markers were dichotomised around the median (except for total CD4+ count which
was dichotomised around 100 cells/μL, rather than the median since it is a standard cut-off,
also used in another study [18], and which resulted in close to equal numbers in both groups),
and the risk and hazard ratios for mortality show the effect of the upper half compared to the
lower half. To generate Kaplan-Meier curves, low numbers of proliferating CD4+ cells and high
numbers of naive CD4+ cells were used as independent variables and their effect assessed using
the log-rank test. All data were analysed using STATA version 13 (StataCorp LP, College Sta-
tion, Texas, USA).
Study Approval
Ethical approval for the NUSTART trial was granted by the London School of Hygiene and
Tropical Medicine, the University of Zambia Biomedical Research Ethics Committee, and the
Medical Research Coordinating Committee of National Institute for Medical Research, Tanza-
nia. The University of Zambia Biomedical Research Ethics Committee approved the current
sub-study (Ref. No. 009-01-11). Each participant provided written or thumbprint informed
consent for participation in the trial.
Results
Characteristics of study participants
A total of 189 HIV-infected adult men and women were enrolled in this sub-study and rando-
mised to either LNS or LNS-VM. Participants were excluded from analysis if some baseline
CD4+ and CD8+ T-cell panel data were missing (n = 3 LNS and n = 5 LNS-VM). Of the
remaining 181 participants, 90 were in the LNS and 91 in the LNS-VM group (Fig 1). Groups
randomised to LNS and LNS-VM were very similar (Table 1). Those who died had lower total
CD4+ cell count, lower grip strength and a small difference in BMI than survivors (Table 1).
T Cell Subsets and Mortality
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Fig 1. Flow of participants through the study.
doi:10.1371/journal.pone.0129928.g001
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Among all participants in this sub study, the median CD4 count at week 0 (enrolment) was 98
(IQR 64, 211) and at week 12 (primary endpoint) was 259 (IQR 166, 389) (p<0.0001).
Mortality between referral for ART and 12 weeks after starting ART
The first aim of this study was to understand whether specific T-cell subsets predict mortality
in a cohort of HIV-infected Zambian adults initiating ART. Of 181 participants, 36 (20%) died
at median (IQR) 5.7 (3.5, 10.1) weeks after ART initiation; 145 (80%) survived through 12
weeks after initiating ART. Patients who died, compared to those who survived, had a lower
total CD4+ T cell count and had more naïve, more central memory, fewer effector memory,
fewer proliferating, fewer gut-homing and fewer gut-homing activated CD4+ T-cells (Table 2).
Patients who died, compared to those who survived, had more senescent, fewer effector or
effector memory, fewer proliferating, more activated proliferating and more activated gut-
homing CD8+ T-cells (Table 2).
In univariate analysis of dichotomised variables, fewer total CD4+, more senescent, or naïve,
fewer proliferating, gut homing or gut homing activated CD4+ T-cells were all predictors of
death (Table 3). More senescent, activated, activated proliferating, or activated gut homing and
fewer effector, effector memory or proliferating, CD8+ T-cells also predicted death (Table 3).
Using a Cox regression model that included all baseline cellular CD4+ and CD8+ subsets
plus BMI, haemoglobin, grip strength and sex, higher numbers of circulating naïve CD4+ and
senescent CD8+ cells were associated with increased mortality, whilst higher numbers of prolif-
erating CD4+ and CD8+ cells were associated with reduced risk of mortality by 12 weeks
Table 1. Baseline clinical and nutritional characteristics of HIV-infected adult Zambianmen and women1.
Survivor status Clinical trial
Variable Died (n = 36) Survived (n = 145) P LNS (n = 90) LNS-VM (n = 91)
Age (years) 36 (34, 42) 35 (30, 41) 0.10 36 (33, 42) 36 (31, 42)
Male 20 (56%) 82 (57%) 0.53 47 (51%) 60 (63%)
Haemoglobin (g/dl) 10.6 (9.2, 12.3) 10.3 (8.7, 11.6) 0.45 10.0 (8.5, 12.0) 10.7 (9.5, 11.4)
Total CD4 (cells/μl) 73 (39, 145) 125 (58, 234) 0.01 119 (66, 264) 87 (55, 205)
Total CD8 (cells/μl) 893 (516, 1270) 856 (583, 1370) 0.51 962 (596, 1304) 974 (674, 1542)
BMI (kg/m2) 16.4 (15.6, 17.2) 16.7 (15.8, 17.8) 0.07 17.0 (16.0, 18.1) 16.6 (15.8, 17.6)
Grip strength (kg) 14.5 (8.7, 16.8) 20.2 (15.4, 24.9) <0.0001 20.2 (14.9, 26.6) 20.0 (15.5, 24.1)
On TB treatment 6 (17%) 49 (34%) 0.045 19 (21%) 36 (39%)
Education
- No education 5 (14%) 19 (13%) 0.85 14 (15%) 10 (13%)
- Primary 18 (50%) 62 (43%) 37 (42%) 42 (44%)
- Secondary 12 (33%) 59 (41%) 36 (40%) 37 (38%)
- Tertiary 1 (3%) 4 (3%) 3 (3%) 2 (5%)
Occupation
- Employed 14 (39%) 82 (57%) 0.17 47 (51%) 49 (52%)
Marital status
- Single 18 (50%) 57 (39%) 0.45 32 (36%) 35 (38%)
- Married 16 (44%) 74 (51%) 52 (55%) 47 (50%)
- Widowed 2 (6%) 14 (10%) 6 (9%) 9 (12%)
1 Mann–Whitney U-tests were used for non-parametric variables and t tests for parametric variables. Continuous characteristics are expressed as median
(interquartile range) and dichotomous characteristics are expressed as n (%). g/dl = grams per decilitre; BMI = body mass index; LNS = lipid-based
nutritional supplement; LNS-VM = LNS with added vitamins and minerals.
doi:10.1371/journal.pone.0129928.t001
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(Table 3). The effect of high versus low CD4+ T-cell proliferation at baseline on subsequent
survival (p = 0.0003 using the log rank test) is illustrated by the Kaplan-Meier curve in Fig 2
(left panel), and the effect of high vs low naïve T-cell numbers (p<0.001) is shown in Fig 2
(right panel).
Survivors randomised to receiving ART with/without vitamin and mineral
The second aim of this study was to investigate the effect of the nutritional intervention on T-
cell subsets after 12 weeks. Of the 145 survivors, 57 withdrew and did not have follow-up sam-
ples collected, so 88 who completed their 12 week follow-up visit were included in this part of
the analysis. Of all the T-cell subsets analysed (Table 4), only the increase in CD4+ recent
Table 2. Baseline CD4 and CD8 T cell subsets among those who survived or died and those in LNS or LNS-VM between referral for ART and 12
weeks after starting Antiretroviral Therapy.
Survivor status (n = 181) Clinical trial (n = 88)
Died (n = 36) Survived (n = 145) LNS (n = 43) LNS-VM (n = 45)
CD4 subsets
Variable (cells/uL) Median (IQR) Median (IQR) P Median (IQR) Median (IQR)
Total count 73 (39,145) 125 (58, 234) 0.01 119 (66, 243) 87 (55, 205)
Thymic emigrants 9 (2, 37) 6 (2, 32) 0.52 7 (2, 32) 6 (2.5, 32.5)
Senescent 4 (0, 21) 7 (2, 17) 0.28 0.5 (0, 9) 2 (0, 6)
Naïve 10 (1, 79) 2 (0, 11) 0.01 2 (0, 5) 6 (2.5, 32.5)
Central memory 5 (0, 25) 1 (0, 4) 0.02 1 (0, 6) 1 (0, 4.5)
Effector memory 46 (26, 75) 62 (28, 137) 0.045 60.5 (32, 172) 62 (18, 127)
Effector 12 (4, 27) 15 (3, 43) 0.45 21.5 (6, 43) 9 (3, 32)
Activated 1 (0, 4) 1 (0, 4) 0.74 2 (0, 5) 2 (1, 9)
Proliferating 12 (7, 22) 28 (12, 80) <0.0001 65 (13, 183) 39 (18, 137)
Proliferating & activated 1 (0, 2) 1 (0, 4) 0.82 0 (0, 3) 1 (0, 8)
Gut homing 23 (6, 45) 42 (19, 95) 0.001 65 (28, 102) 40 (23, 78)
Gut homing & activated 6 (1, 17) 18 (8, 40) <0.0001 15 (7, 27) 11 (4, 25)
CD8 subsets
Total count 893 (516,1270) 856 (583,1370) 0.51 962 (596, 1304) 974 (674, 1542)
Thymic emigrants 354 (220, 548) 302 (161, 546) 0.34 279 (139, 542) 277 (155, 444)
Senescent 251 (122, 374) 101 (15, 320) 0.01 148 (0, 444) 157 (0, 491)
Naïve 11 (2, 51) 29 (7, 56) 0.10 44 (22, 125) 36 (8, 55)
Central memory 2 (0, 15) 1 (0, 13) 0.67 0 (0, 10) 0 (0, 14)
Effector memory 41 (6, 84) 102 (13, 279) 0.01 187 (51, 381) 231 (141, 411)
Effector 131 (34, 251) 268 (24, 707) 0.01 598 (252, 978) 589 (394, 1060)
Activated 73 (22, 186) 39 (7, 214) 0.33 78 (101, 312) 88 (6, 464)
Proliferating 1 (0, 7) 19 (1, 419) <0.0001 216 (0, 626) 324 (0, 704)
Proliferating & activated 205 (53, 581) 63 (16, 278) 0.004 24 (4, 128) 63 (13, 249)
Gut homing 378 (211, 607) 450 (281, 786) 0.13 505 (292, 804) 513 (330, 914)
Gut homing & activated 20 (9, 67) 8 (1, 20) 0.001 6 (0, 14) 4 (0, 12)
*p-values determined using Mann–Whitney U-tests. Subsets of CD4+ T cells are presented as median (interquartile range) absolute cells/μL and deﬁned
as gut homing: α4+β7+, homing activated: α4+7+CD25+, recent thymic emigrants: CD45RA+CD31+, senescent: CD57+, naive: CCR7+CD45RA+, central
memory: CCR7+CD45RA-, effector memory: CCR7-CD45RA-, effector: CCR7-CD45RA+, activated: HLA-DR+, proliferating and activated HLD-DR+Ki 67+;
and proliferating: Ki67+.
doi:10.1371/journal.pone.0129928.t002
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thymic emigrants was significantly different in the participants allocated to receive LNS-VM
compared to LNS.
Discussion
Consistent with previous reports from sub-Saharan Africa [4,5], we found high mortality
(20%) within 12 weeks of initiating ART among a cohort of malnourished HIV-infected Zam-
bian adults with advanced stages of HIV-infection. We explored T-cell subsets as predictors of
mortality and found that they predict death and displace total CD4+ count in multivariate
models. The nutritional intervention we trialled did not affect these subsets, so we have not yet
found a tool for manipulating T-cell subsets or ameliorating the impact of undernutrition on
mortality during ART initiation [17]. In our analysis, a high number of naïve CD4+ T-cells and
Table 3. Immunological Risk Factors for DeathWithin 12Weeks of Initiating Antiretroviral Therapy.
Univariate Multivariate
Variable Unadjusted HR (95% CI) Adjusted HR (95% CI)
CD4 Total 0.51 (0.27 – 0.95) *
CD4 Thymic emigrants 0.89 (0.49–1.59)
CD4 Senescent 1.97 (1.03–3.76) *
CD4 Naïve 2.25 (1.78–4.29) * 2.88 (1.39 – 5.97) *
CD4 Central memory 1.46 (0.81–2.63)
CD4 Effector memory 0.49 (0.27–0.94)
CD4 Effector 0.70 (0.38–1.27)
CD4 Activated 0.68 (0.36 – 1.30)
CD4 proliferation 0.29 (0.14 – 0.60) * 0.43 (0.19 – 0.98) *
CD4 Proliferating & activated 0.68 (0.36 – 1.30)
CD4 Gut homing 0.39 (0.20–0.76) *
CD4 Gut homing activated 0.39 (0.20–0.76) *
CD8 Total 1.13 (0.63 – 2.03)
CD8 Thymic emigrants 1.42 (0.78–2.57)
CD8 Senescent 3.03 (1.51–6.08) * 6.62 (2.94 – 14.88) *
CD8 Naïve 0.64 (0.35–1.18)
CD8 Central memory 1.16 (0.64–2.08)
CD8 Effector memory 0.51 (0.27–0.95) *
CD8 Effector 0.52 (0.28–0.98) *
CD8 Activated 1.83 (0.99–3.38) *
CD8 Proliferation 0.25 (0.12–0.54) * 0.12 (0.05 – 0.28) *
CD8 Proliferating & activated 1.79 (0.97–3.31) *
CD8 Gut homing 0.72 (0.40–1.31)
CD8 Gut homing and activated 2.07 (1.10–3.88) *
BMI 0.66 (0.37 – 1.19)
Hb 0.38 (0.14 – 1.07)
Sex 0.97 (0.54 – 1.74)
Grip strength 0.23 (0.11 – 0.50) * 0.23 (0.10 – 0.53)*
All variables were calculated using absolute numbers. 36 participants died within 12 weeks of follow up. All variables were dichotomized; univariate
logistic regression models were constructed comparing the upper half of the distribution with the lower half. Multivariate analysis was done using a Cox
regression model, and was adjusted for, total CD4 and CD8 counts plus BMI, haemoglobin, sex and grip strength. HR = hazard ratio
* = signiﬁcant CI (conﬁdence interval).
doi:10.1371/journal.pone.0129928.t003
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a high number of senescent CD8+ T-cells at ART initiation were associated with mortality,
whilst a high number of proliferating CD4+ or CD8+ T-cells were associated with survival.
Fig 2. Survival among HIV-infected adults initiating antiretroviral therapy according to proliferating and naïve CD4 cell counts. (Left) Kaplan-Meier
plot of survival over time among HIV-infected adults with high (dashed line) or low (solid line) absolute number of CD4+ cells expressing the proliferation of
marker Ki67 (p = 0.0003 using log rank test). (Right) Kaplan-Meier plot of survival over time among HIV-infected adults with low (dashed line) or high (solid
line) absolute number of CD4+ cells expressing the naïve markers CD45RA and CCR7 (p<0.001 using the log rank test).
doi:10.1371/journal.pone.0129928.g002
Table 4. Changes in T cell subset markers in patients receiving supplements with (LNS-VM) or without (LNS) additional vitamins andminerals.
CD4 CD8
Change in LNS-VM group
(N = 45)
Change in LNS group
(N = 43)
Change in LNS-VM group
(N = 45)
Change in LNS group
(N = 43)
Variable Median (IQR) Median (IQR) P Median (IQR) Median (IQR) P
Total count 126 (82, 210) 122 (81, 204) 0.98 -27 (-284, 173) 7 (-300, 213) 0.83
Thymic emigrants 8.5 (1.5, 41) 29 (7, 61) 0.01 144 (-27, 306) 87 (20, 221) 0.88
Senescent -1 (-11, 8) -0.5 (-10, 11) 0.93 44 (-112, 191) 10 (-90, 194) 0.81
Naïve 2 (-2, 28) 7 (0, 30) 0.27 46 (0, 221) 32 (-19, 380) 0.90
Central memory 5 (-2, 27) 6.5 (1, 25) 0.40 11 (0, 66) 20 (0, 79) 0.34
Effector memory 91 (39, 145) 64 (25, 169) 0.45 -71 (-141, 30) -65 (228,57) 0.81
Effector 7 (-1, 32) 3 (-10, 30) 0.27 -130 (-299, 72) -78 (-542, 133) 0.80
Activated 4 (0, 16) 4 (-1, 17) 0.73 194 (-31, 431) 196 (52, 371) 0.94
Proliferation 50 (-30, 126) 62 (-6, 106) 0.69 377 (-98, 877) 350 (25, 782) 0.81
Proliferating &
activated
1 (-2, 8) 2 (-1, 10) 0.48 25 (-16, 174) 41 (-16, 123) 0.72
Gut homing -39 (-78, -22) -64 (-102, -27) 0.33 -51 (-186, 55) -65 (-273, 62) 0.93
Gut homing &
activated
-8 (-15, -2) -11 (-20, 0) 0.62 0 (-4, 4) 0 (-6, 3) 0.90
*p-values determined using Wilcoxon rank-sum tests. Changes in subsets of CD4+ and CD8+ T cells are presented as median (interquartile range
absolute cells/μL and deﬁned as gut homing: α4+β7+, homing activated: α4+β7+CD25+, recent thymic emigrants: CD45RA+CD31+, senescent: CD57+,
naive: CCR7+CD45RA+, central memory: CCR7+CD45RA-, effector memory: CCR7-CD45RA-, effector: CCR7-CD45RA+, activated: HLA-DR+ and
proliferating and activated: HLD-DR+Ki 67+; proliferating: Ki67+.
doi:10.1371/journal.pone.0129928.t004
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We found a consistent effect of proliferating CD4+ and CD8+ T-cells on mortality, such that
higher levels of proliferation were associated with protection against death. Other studies have
shown that CD4+ proliferation correlates with viral load; it has been suggested that this is
because proliferating (Ki67+) CD4+ T-cells can efficiently support virus replication [19,20] and
lead to more rapid progression to AIDS [21]. In our cohort of malnourished adults, however,
the effect was the opposite. Importantly, our cohort was moderately or severely malnourished,
and this may be a critical point of difference. We speculate that T-cell proliferative ability
reflects a greater ability to respond to co-infections, which are the most frequent cause of mor-
tality after ART initiation [22]. By contrast, a low proportion of proliferating cells in those who
subsequently died may signify immune exhaustion, which is known to affect proliferative
capacity and may be a pre-terminal event in a malnourished individual. Although we did not
evaluate cellular exhaustion markers, other studies have shown elevated T-cell expression of
PD-1 [23], CTLA-4 [24] and TIM-3 [25] in advanced HIV disease, which correlate inversely
with cellular proliferative capacity.
We also found that higher numbers of senescent CD8+ T-cells predict mortality. During
HIV infection persistent T-cell activation drives proliferation that results in the accumulation
of senescent, antigen-experienced memory T-cells with reduced expression of CD28 and
increased expression of CD57 [26]. Expression of CD57 has been linked to greater resistance to
apoptosis in CD8+ T lymphocytes during HIV infection, facilitating accumulation [27]. Since
CD8+ T-cells are crucial to the recognition and clearance of virus-infected cells [28,29], a high
number of senescent CD8+ T-cells may underlie the inability of T-cell immunity to suppress
virus adequately.
It has been reported that naïve CD4+ T-cells are progressively depleted during HIV infec-
tion because of their frequent activation and differentiation into memory cells [30]. A study by
Schacker and colleagues found that patients with relatively high numbers of naive CD4+ T-cells
were less likely to have failure of immune reconstitution with ART and had lower risk of
opportunistic infections and mortality [9]. By contrast, low pre-ART naïve CD4+ T-cell fre-
quencies predicted poor ART-mediated CD4+ T-cell recovery in other studies [31,32]. Addi-
tionally, Zhang and colleagues recently showed that increases in naïve CD4+ T-cells following
ART initiation independently predicted subsequent CD4+ T-cell increases [33]. However, our
data show that having more naïve cells at baseline increased the likelihood of death during
ART in this Zambian cohort with advanced disease. We speculate that predominance of naïve
cells at baseline may reflect a permanent loss of important memory cell clones, which cannot
be reconstituted despite effective ART. Again, this might be critically dependent on nutritional
status (if severe malnutrition imposes a replication constraint on proliferating cell lineages)
and/or in a setting where opportunistic infections are highly prevalent. Further studies in dif-
ferent patient groups may clarify these differences.
Although there was a small but significantly greater rise in total CD4+ count in the LNS-VM
vs LNS group in the main NUSTART trial (difference +25 cells/μL; p = 0.02) [17], we found no
major differences among T-cell subsets in this sub-study. The only exception was the popula-
tion of recent thymic emigrants, which increased more in the LNS group than in the LNS-VM
group. We speculate that there may be a constraint on proliferation imposed by severe malnu-
trition and the LNS alone might not be sufficient to permit restoration of thymic output.
This study had several strengths and some limitations. The major strength of this study is
the detailed immunophenotyping that was conducted in malnourished HIV-infected adults
with advanced disease, which allowed us to address questions related to early mortality,
together with the randomized trial design, which allowed us to evaluate the impact of a nutri-
tional intervention on lymphocyte subsets. Study limitations include lack of viral loads, which
are not generally available in sub-Saharan Africa for monitoring ART response, and the small
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sample size at 12 weeks, because of loss to follow-up. Because the participants in this study had
advanced disease (median CD4 at ART initiation 98 cells/μL) and malnutrition, our findings
may not be generalizable to the larger population of HIV-infected adults initiating ART in sub-
Saharan Africa, although it is worth noting that the mean CD4 count at ART initiation in sub-
Saharan African programs in 2002 was 152 cells/μL and has not increased significantly since
then, meaning that many patients still start ART in the setting of advanced immunodeficiency
[34].
In this report of a sub-study of a large clinical trial in adults initiating ART, we found no
substantial differences in the effects of a nutritional intervention on specific T-cell subsets, but
found that baseline numbers of proliferating CD4+ and CD8+ cells, naïve CD4+ cells, and
senescent CD8+ cells at ART initiation impacted early mortality on ART. These findings
provide insights into the immune dysfunction of AIDS in the context of malnutrition and sug-
gest that baseline immune abnormalities in this population render individuals susceptible to
co-infections, which are associated with very high mortality despite ART initiation. Whether
patients would benefit from adjunctive infection control interventions at initiation of anti-
retroviral therapy (such as additional antiretrovirals and a package of anti-microbial drugs)
in addition to a nutritional intervention, is currently being explored in sub-Saharan Africa
(REALITY trial; ISRCTN43622374). Our findings also argue strongly for earlier initiation of
antiretroviral therapy in sub-Saharan Africa [34], because the immune perturbations that char-
acterize advanced immunodeficiency are difficult to reverse.
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